|
|
Anavex to present at Alzheimer’s Association International Conference on Alzheimer's Disease
Sources News Release
http://www.sources.com/Releases/NR1366.htm
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 15/07/2011
Year Published: 2011
Resource Type: Article
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease (AD) currently in Phase I clinical trials, will be presented in two poster sessions at the 2011 Alzh
Abstract: Hoboken, NJ – July 15, 2011 -- Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease (AD) currently in Phase I clinical trials, will be presented in two poster sessions at the 2011 Alzheimer’s Association International Conference on Alzheimer’s Disease (AAICAD) in Paris, France.
Both ANAVEX 2-73 posters will be presented by Tangui Maurice, PhD, CNRS Research Director, Team II Endogenous Neuroprote...
To read the full release go to http://www.sources.com/Releases/NR1366.htm
Topics
|
AlterLinks
c/o Sources
© 2025.
|
|
|
|
